The clinical-stage biopharmaceutical company Phio Pharmaceuticals Corp. (NASDAQ: PHIO), which specializes in siRNA-based cancer treatments, saw a sharp rise in stock value after launching a new strategic strategy. As of the latest transaction data, PHIO shares were up 7.42% to $3.18, reflecting investor confidence in the company’s growing emphasis.
Increasing the Therapeutic Potential of INTASYL
The business is developing its in-house INTASYL gene silencing technology, which consists of a pipeline of about 30 chemicals at the moment. With its recently revealed strategic plan, Phio hopes to raise awareness of the portfolio’s wider applications.
This action comes after the current Phase 1b dosage escalation study of PH-762, an INTASYL chemical used to treat skin cancer, showed encouraging interim safety and effectiveness results. Preclinical and clinical evidence suggest that INTASYL may find application in a broader number of therapeutic domains.
Change in Leadership to Promote Development
Phio announced significant leadership changes that would take effect on June 9, 2025, in support of these goals. Former Chief Financial Officer Mr. Robert Infarinato has been promoted to Vice President of Strategic Development. Mr. Infarinato will spearhead business development initiatives aimed at extending the INTASYL platform’s strategic reach in his new position.
With more than thirty years of expertise in operations and finance, Mr. Infarinato has held high-level roles such as Chairman of the Board of Trustees of Abington Health and Executive Vice President and CFO of a global services organization.
Strengthened Finance Leadership
Ms. Lisa Carson was appointed Vice President of Finance and Administration at the same time. With more than 20 years of experience in finance leadership, Carson joined Phio in May 2025.
She previously served as Controller and Vice President of Finance at Prelude Therapeutics being a key player in the IPO and growth of the business over time. Moreover, her previous roles at TELA Bio and PhaseBio Pharmaceuticals attest to her expertise in biopharma finance operations.
These key hires demonstrate Phio’s dedication to developing its cutting-edge siRNA technology and increasing shareholder value via focused research and strengthened leadership.
Leave a Reply